Microarray
Technology Could Help Predict Response to Adjuvant Therapy for Breast Cancer
Behind the Cancer Headlines®
Microarray technology could be used to tailor therapy according to the individual, and prevent breast cancer patients from having to undergo painful unsuccessful therapies. In a study published in the journal Breast Cancer Research, researchers analyzed tumor tissue samples and identified a group of 64 genes that can be used to predict a patient's response in the five years after adjuvant therapy for breast cancer.
Identifying patients whose breast tumors express these genes could potentially be used to predict which patients would not benefit from adjuvant therapy, and avoid patients being given therapies with the potential of causing more harm than good.
A team of researchers led by Jonas Bergh from the Karolinska Institutet in
An analysis of the genes expressed in the tumors of all 159 patients showed that 64 genes were used to separate the patients with good and poor prognoses. The researchers then tested the predictive value of the group of 64 genes compared with three currently used clinical markers. Using the expression patterns of the 64 genes identified by the researchers gave significantly better (P=0.007) prediction rates than histological grading, tumor stage and age - which are all accepted prognostic markers for breast cancer.
The present lack of criteria to help tailor breast cancer
treatment to individual patients indicates a need to develop new techniques for
better prediction of how patients will respond to adjuvant treatments. The
researchers suggest that the technique of DNA microarray
analysis could be developed to help breast cancer patients who do not benefit
from adjuvant therapy, and avoid painful unnecessary treatments and wastage of
healthcare resources.
SOURCE:
Breast Cancer Research,
online edition,